Paulina Karp

Paulina Karp

Auto-generated profile, based on publicly available information

Paulina Karp


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMarcelina Kądziela
Marcelina Kądziela
MKMagdalena Kutwin
Magdalena Kutwin
PKPaulina Karp
Paulina Karp
Anna WozniackaAnna Wozniacka
Anna Wozniacka
Vitiligo is a persistent autoimmune disease characterized by progressive depigmentation of the skin caused by the selective destruction of melanocytes. Although its etiopathogenesis remains unclear, multiple factors are involved in the development of this disease, from genetic and metabolic factors to cellular oxidative stress, melanocyte adhesion defects, and innate and adaptive immunity. This review presents a comprehensive summary of the existing knowledge on the role of different cellular mechanisms, including cytokines and chemokines interactions, in the pathogenesis of vitiligo. Although there is no definitive cure for vitiligo, notable progress has been made, and several treatments have shown favorable results. A thorough understanding of the basis of the disease uncovers promising drug targets for future research, providing clinical researchers with valuable insights for developing improved treatment options.

1 January 2024 in Dermatology Review
Verified
Journal Article
Open access
PDF file
PKPaulina Karp
Paulina Karp
NLNatalia Lewkowicz
Natalia Lewkowicz
AŻAgnieszka Żebrowska
Agnieszka Żebrowska
Mucosal melanoma malignum (mMM) is a rare and aggressive malignancy that carries a poor prognosis. Most commonly, it develops on the mucous membranes in the head and neck region, and within the genitalia. Because of its anatomical location and absence of early symptoms, diagnosing mucosal...

10 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMagdalena Kutwin
Magdalena Kutwin
PKPaulina Karp
Paulina Karp
MKMarcelina Kądziela
Marcelina Kądziela
ASAlicja Siennicka
Alicja Siennicka
Agnieszka ŻebrowskaAgnieszka Żebrowska
Agnieszka Żebrowska
Dermatomyositis (DM) is a rare, autoimmune inflammatory myopathy characterized by a heterogeneous clinical course and complex etiopathogenesis. Although classically defined by the coexistence of muscle inflammation and distinctive skin lesions, DM frequently presents as a systemic disease, and, in some patients, cutaneous manifestations may precede muscle involvement or represent the sole clinical feature. The spectrum of skin lesions in DM is broad and includes pathognomonic, characteristic, rare, or atypical manifestations, ranging from classic Gottron’s sign and heliotrope rash to uncommon subtypes such as vesiculobullous dermatomyositis, Wong-type dermatomyositis, or flagellate dermatitis. Particular cutaneous phenotypes often correlate with distinct clinical subtypes, autoantibody profiles, systemic involvement, and prognosis. The diversity of dermatological presentations and their resemblance to other dermatoses may delay accurate diagnosis, especially in amyopathic and hypomyopathic forms of the disease. The aim of this review is to comprehensively discuss the wide spectrum of cutaneous manifestations of dermatomyositis, emphasize less recognized and rare dermatological clinical presentations, and highlight their diagnostic and prognostic significance. However, histopathological examination may support the diagnostic process in challenging cases. Early identification of characteristic skin lesions remains crucial for prompt diagnosis, appropriate screening for systemic complications and malignancy, and optimal management. Close interdisciplinary cooperation among dermatologists, rheumatologists, and other specialists is essential to ensure accurate diagnosis and improve outcomes in patients with dermatomyositis.

9 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MKMarcelina Kądziela
Marcelina Kądziela
MKMagdalena Kutwin
Magdalena Kutwin
PKPaulina Karp
Paulina Karp
Anna WozniackaAnna Wozniacka
Anna Wozniacka
Vitiligo is a chronic autoimmune disease characterized by progressive depigmentation of the skin caused by the selective destruction of melanocytes. Although its etiopathogenesis remains unclear, multiple factors are believed to be involved, including genetic and metabolic factors linked to cellular oxidative stress, melanocyte adhesion defects, innate and adaptive immunity. The aim of this review is to provide an overview of the current state of knowledge regarding the role of different cellular mechanisms, including cytokines and chemokines interactions in the pathogenesis of vitiligo. Although there is no definitive cure for vitiligo, excessive progress has been made and several treatments have shown favourable results. A thorough understanding of the basis of the disease, uncover promising drug targets for future research, providing clinical researchers with valuable insights for developing improved treatment options.